On December 28, the 5th i Hope Medical Oncology Innovation International Forum and the 5th i Hope Voice Young Doctors Speech Conference were successfully held in Beijing. The chairman of the meeting was Professor Qin Haifeng, founder of i Hope Medicine, who said that malignant tumors are one of the public health problems that seriously threaten the healthy life of Chinese residents, and it is the responsibility and mission of every medical worker to participate in cancer prevention and control. i Hope that all clinical experts can actively use the platform of I Hope Medicine to actively carry out academic exchanges, jointly improve academic level, and bring better treatment to cancer patients. Professor Shi Yuanyuan, chairman of Shenzhen Cell Valley, was invited to attend and participate in answering the questions of experts.
As an important guest of the forum, Professor Shi Yuanyuan, chairman of the board, delivered a speech on the theme of "Research Progress of NK and CAR-NK Cell therapy", introduced the current international research progress of NK and CAR-NK therapy in detail, and also introduced the latest progress and breakthroughs made by Shenzhen Cell Valley in this field, which was highly recognized by clinical experts of various schools. Professor Shi Yuanyuan pointed out that natural killer cells (NK cells) account for 5% to 15% of adult peripheral blood lymphocytes and are important innate immune cells. NK cells play a key role in tumor immune surveillance and kill tumor cells by directly dissolving and secreting cytokines. The main goal of NK cell therapy is to improve a patient's ability to fight cancer or other diseases by activating or enhancing the function of NK cells. CAR-NK has better efficacy in the treatment of hematoma and solid tumor, and has the advantages of high industrial production capacity, low cost and side effect risk. Although CAR-NK has great application prospects, there are still some major card points that hinder its successful application in the clinical side. Shenzhen Cell Valley one-on-one to solve various difficulties of CAR-NK - low transduction efficiency, difficult production and proliferation, poor sustainability, to solve the limitations of clinical transformation of CAR-NK cells. At the same time, Shenzhen Cell Valley has owned independent intellectual property rights of the development and industrial application of BaEV coated retrovirus packaging engineering cell lines, the positive rate of transducing T cells and NK cells is more than 90%, and the positive rate has not decreased.
In the answer to expert questions and answers, a number of clinical medical experts asked Professor Shi Yuan for advice on the advantages of allogeneic NK cells and cell therapy policies. Professor Shi Yuanyuan shared that APUNK™, a non-modified allogeneic NK cell launched by Shenzhen Cell Valley, can multiply more than 10,000 times in vitro, which can meet the number of cells required for clinical infusion. The purity of the prepared NK cells was greater than 99%, and the T cells < 0.1%, which was much higher than the allograft standard recognized by the US FDA (NK cells > 90%, T cells < 5%). In addition, he elaborated the historical development of cell therapy-related policies. As a legislative consulting expert on the Regulations on the Promotion of Cell and Gene Industry in Shenzhen Special Economic Zone and the Regulations on the Promotion of Cell and Gene Industry in Xiamen Special Economic Zone, Professor Shi Yuanyuan foresaw the future of policy development with great foresight. The forum focused on the fields related to tumor precision therapy, providing a multi-dimensional communication platform for participants. By participating in this forum, Shenzhen Cell Valley showcases its achievements in innovation and industrialization in the field of cell therapy. The successful holding of the forum not only promotes the progress of precision cancer treatment, can bring better curative effect to tumor patients, effectively extend the survival period of patients, but also provides a new growth impetus for the development of the medical and health industry, and helps forge ahead for the common vision and human health cause.